Proven immune markers continue to preserve their relevance for clinical final decision-building in breast cancer treatment with even extended meanings. Estrogen receptor (ER) level should not only be classified in constructive or destructive. Very low ER degrees ≤ten% of labeled cells has to be managed in different ways (LoE https://sidneye197aip4.popup-blog.com/profile